Clinical Trial Update: Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant anti-PD-1 antibody toripalimab alone or with chemotherapy in head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN